U.S. manufacturing reshoring is creating a new investment opportunity for industrial companies as businesses increase domestic production, strengthen supply chains and spend heavily on factories, machinery and infrastructure. The trend is gaining additional momentum from the rapid expansion of AI

U.S. biotech industry is gaining fresh momentum as personalized cancer vaccine research produces encouraging clinical results and pharmaceutical companies accelerate efforts to develop next-generation cancer treatments. The progress is strengthening investor interest in mRNA technology while highlighting the growing role

Moderna cancer vaccine research is drawing renewed attention from investors after new clinical data strengthened the outlook for the company’s personalized cancer vaccine program developed with Merck. The results have reinforced expectations that individualized mRNA vaccines could become an important

U.S. AI spending is entering a more cautious phase as companies continue pouring money into data centers, computing capacity and artificial intelligence systems while investors increasingly question whether the enormous infrastructure investments will generate sufficient returns. The debate is no

Corporate bond issuance in the United States has surged to $1.68 trillion through mid-August 2026, with technology companies increasingly turning to debt markets to finance the enormous cost of artificial intelligence infrastructure. The increase represents a roughly 27% jump from

U.S. industrial companies are finding a new growth engine as artificial intelligence investment drives a massive expansion of data centers, power infrastructure and related manufacturing. The boom is creating opportunities for manufacturers that were once far removed from the technology